Disclosed herein are motuporamine mimic agents and methods of making and using same. Particularly exemplified are motuporamine mimic agents comprising cytotoxic activity and/or anti-metaplastic activity.
[EN] ANTI-METATSTATIC AGENTS PREDICATED UPON POLYAMINE-MACROCYCLIC CONJUGATES<br/>[FR] AGENTS ANTIMÉTASTASIQUES À BASE DE CONJUGUÉS MACROCYCLIQUES DE POLYAMINE
申请人:UNIV CENTRAL FLORIDA RES FOUND
公开号:WO2013148219A1
公开(公告)日:2013-10-03
Disclosed herein are novel motuporamine compounds that act as anti-metastatic agents with low toxicity and high anti-migration activity. The non-toxic, anti-metastatic agents may be given to patients with potential or actual metastatic cancers, such as pancreatic cancers, alone in combination with known and/or new therapies to help block the growth and spread of tumor(s)..
Tandem Conjugate Additions and 3-Aza-Cope Rearrangements of Tertiary Allyl Amines and Cyclic α-Vinylamines with Acetylenic Sulfones. Applications to Simple and Iterative Ring Expansions Leading to Medium and Large-Ring Nitrogen Heterocycles
作者:Mitchell H. Weston、Katsumasa Nakajima、Thomas G. Back
DOI:10.1021/jo800600a
日期:2008.6.1
Tertiary acyclic allyl amines and tertiary cyclic α-vinyl amines undergo conjugate additions to acetylenic sulfones to produce zwitterion intermediates, followed by 3-aza-Cope rearrangements. In the case of cyclic α-vinyl amines, the process results in ring-expansion, providing a novel route to 9- to 17-membered cyclic amines. The Hammett plot for the reaction of 8b with 2a−2f shows ρ = +1.19, which
Disclosed herein are motuporamine mimic agents and methods of making and using same. Particularly exemplified are motuporamine mimic agents comprising cytotoxic activity and/or anti-metaplastic activity.
ANTI-METASTATIC AGENTS PREDICATED UPON POLYAMINE MACROCYCLIC CONJUGATES
申请人:Phanstiel, IV Otto
公开号:US20150057361A1
公开(公告)日:2015-02-26
Disclosed herein are novel motuporamine compounds that act as anti-metastatic agents with low toxicity and high anti-migration activity. The non-toxic, anti-metastatic agents may be given to patients with potential or actual metastatic cancers, such as pancreatic cancers, alone in combination with known and/or new therapies to help block the growth and spread of tumor(s).